Tata India Pharma & Healthcare Fund

A Sectoral/Thematic Fund scheme from Tata Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF277K019A3).

NAV ₹39.6495 on 16 November 2026.

Expense ratio

Total expense ratio 1.09% a year for the Direct · Growth plan, as AMFI published it on 28 October 2026: base expense ratio 0.63%, brokerage 0.11%, transaction costs 0.01%, statutory levies including GST 0.34%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year10.1%12.3%-11.0%0.250.25
3 years19.1%13.4%-16.8%0.900.86
5 years15.4%13.1%-16.8%0.640.63
10 years16.0%15.3%-18.5%0.590.59

Category rank: 11th of 13 Direct-Growth funds in Sectoral/Thematic Fund — Pharma, by 3-year Sortino ratio.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 99.7% of the portfolio.

  1. Sun Pharmaceutical Industries Limited — 7.89%
  2. Abbott India Limited — 5.66%
  3. Divi's Laboratories Limited — 5.41%
  4. Healthcare Global Enterprises Limited — 5.25%
  5. Dr. Reddy's Laboratories Limited — 5.14%
  6. Torrent Pharmaceuticals Limited — 4.73%
  7. Apollo Hospitals Enterprise Limited — 4.55%
  8. Max Healthcare Institute Limited — 4.28%
  9. Rainbow Childrens Medicare Limited — 4.02%
  10. Sai Life Sciences Limited — 3.22%

Plans

Other funds in Sectoral/Thematic Fund

All 257 funds in Sectoral/Thematic Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.